IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 15, Issue 12 Ver. V (December. 2016), PP 12-14
www.iosrjournals.org

Prognostic classification of Breast carcinoma on molecular basis using ER, PR, Her-2/neu and ki67: A study conducted on 45 patients in RIMS, Ranchi, Jharkhand, India

Rabindra Kumar Singh[1], Saurav Banerjee[2], Ramesh Kumar Shrivastav[3], Purnima Bharati[4,] Anil Kumar Sinha[5]

[1]*Assistant Professor, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.*
[2]*Tutor, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India*
[3]*Professor, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.*
[4]*Junior Resident, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India*
[5]*Assistant Professor, Department of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.*

Abstract:
Objective: *To classify the cases of breast carcinoma coming to RIMS, Ranchi into Luminal A,B,Her-2/neu and basal like using IHC Markers-ER,PR,Her-2/neu and ki67*
Materials and methods: *In our study on 45 patients with breast carcinoma, all of them being women were taken into account and the expression of Hormonal ,markers ER,PR, Her-2 and ki67 were determined by immunohistochemistry and classification into Luminal A,B,Her-2 and Basal like were done subsequently.*
Results: *The mean age of patients was 53.17 years. Of 45 patients, 17 patients (37.77%) had breast cancer with metastasis and 28(62.22%) without metastasis. Nottingham modification of Scarff Bloom Richardson grading was-Grade I in 18 patients, Grade II in 15 patients and Grade III in 12 patients. Depending on IHC markers ER, PR, Her-2/neu and ki67,Luminal A patients were 34(75.55%),Luminal B were 8(17.77%),Her-2/neu-1(2.22%) and Basal like-2(4.44%).*
Keywords: *Breast cancer, Immunohistochemistry, molecular classification, Luminal A,B*

I. Introduction

Breast carcinomas is the most common cancer in women worldwide contributing about 20% of cancer deaths in women and are notably among the most significant concern for any women in today's world .Carcinomas of the breast show marked variation in regard to clinical presentation, biological behavior, and response to therapy. For the past several decades. the classification and management of breast carcinoma were primarily based on clinicopathologic (morphology, size, grade, nodal status, etc.) characteristics. Even among histologically similar tumors, these characteristics could not always offer accurate prognostic and predictive information. Over the last few decades, the immunophenotypical profile of a breast carcinoma has achieved a greater prognostic and predictive importance. In this study we have attempted to classify 45 breast carcinoma samples coming to RIMS, Ranchi, India into Luminal A,B,Her2/neu and Basal like for better prognostic outcome of the patients.

II. Discussion

The aim in modern medicine is to identify patients who have an unfavorable prognosis – or even better, to identify patients who may be capable of benefiting from an improved prognosis associated with a specific form of treatment. Similar to other carcinomas of various anatomic sites, the development of invasive breast carcinoma also involves multiple genetic alterations-and this has long been exploited for prognostication[1,7]. The pioneering molecular classification system for breast carcinoma was developed by Perou et al in 2000[1]. Depending on the intrinsic gene expression pattern using cDNA Microarray,four molecular subtypes of breast carcinomas were identified: "luminal", "HER2-enriched, "basal-like' and "normal breast-like'. The *"luminal* group"' of carcinomas were largely hormone receptor[1,5] and express luminal epithelial genes-traits similar to those of normal luminal epithelial cells. The "HER2-enriched group" was mainly composed of breast carcinomas with amplification of the HER2 gene. The "basal like group" was ER(-), and frequently corresponded to the triple negative breast carcinomas (TNBCs, i.e., ER(-), PR(-), and HER2(-)). This group of tumors was immunoreactive for cytokeratin (CK) 5/6 and CK17, similar to the reactivity pattern observed in myoepithelial cells of the normal breast epithelium (i.e., "basal" cells, hence the term applied to this group). The category of tumors called "normal breast-like" had a gene expression pattern similar to that observed in normal

breast tissue. It later became evident that the last subtype is most likely an artifact rather than a genuine type of breast cancer, resulting from contamination of tissue samples with high levels of normal breast tissue and paucity of the tumour, and may not exist at all. Luminal group was further divided into "A" and "B" depending on the proliferative rate[2].Luminal B tumors responded less to hormonal therapy, and more to chemotherapy, relative to luminal A tumors[3,4]. In general, luminal B tumors had a poorer prognosis than did luminal A tumors[4]. Triple negative breast cancers have the worst prognosis overall[1,6]. Table no. 1 shows the chief features of the molecular subtypes. The various molecular classifications of breast carcinomas attempt to capture the intrinsic biologic variances among these tumors and stratify them into clinically relevant groups beyond those possible by ER/PR/HER2 testing. Most significantly, molecular classifications seek to stratify breast carcinomas into molecularly distinct subtypes with an aim to employ "druggable" targeted therapy.

Using ER, PR, Her2/neu and ki67 markers, molecular classification of Breast carcinoma into Luminal A, B, Her 2 enriched and Basal like was done in this study and the results are shown in table 2. This clearly implicates that 75.55% of Luminal A patients can benefit only from hormonal therapy alone and neoadjuvant chemotherapy is not required. Classifying breast carcinoma into luminal B is also helpful as we can understand that these patients will not benefit from hormonal therapy and chemotherapy will be required. Furthermore, these patients will have a poorer prognosis as there are increased chances of relapse. By use of one extra IHC marker that is ki67, better or worse outcome can be easily predicted in a patient of breast carcinoma and the type of therapy required can also be predicted.

III. Tables

	Luminal A	**Luminal B**	**Her2/neu enriched**	**Basal like**
Immunoprofile ER,PR HER2 and ki67	ER and/or PR +ve Her2/neu –ve Ki67 index<14%	ER and/or PR +ve Her2 +/- ve Ki67 index≥14%	ER and PR –ve Her2 +ve, High proliferative rate	ER,PR -ve Her2 –ve, High proliferative rate
Prognosis	Good	Intermediate	Poor	Poor
Distant relapse	Distant relapse Peak at 4 y, and risk of relapse prolongs	Distant relapse Peak at 4 y, and risk of relapse prolongs	Peak at 4-6 y, but risk persistent over 10-15 years.	Peak at 2 years,then reduced to minimal over 10 years
Response to hor monal therapy	Good	Poor with Hormonal therapy only	No response	No response
Response to chemotherapy	Poor	Intermediate	Good, better with trastuzumab	Good
Histologic grade	Low to intermediate	Intermediate	High	High

Table 1-Chief features of molecular subtyping of Breast carcinoma

Molecular subtype	**No. of patients**	**percentage**
Luminal A	34	75.55%
Luminal B	8	17.77%
Her2 enriched	1	2.22%
Basal like	2	4.44%

Table 2- Results as obtained after using IHC markers on 45 patients.

IV. Conclusion

Using ER, PR, Her2/neu and ki67, molecular classification of breast carcinoma into Luminal A, B, Her2/neu enriched and Basal like was done in this study and it showed that nearly three fourth of the patients fall in Luminal A category and they can benefit only from hormonal therapy alone and neoadjuvant chemotherapy is not required, and have an overall good prognosis. Neoadjuvant chemotherapy is required in 21.22% patients belonging to Luminal B and Basal like category and they have an overall poorer prognosis. Trastuzumab therapy can be started in Her2/neu enriched subtype.

A beforehand knowledge of these immunohistochemical markers can help oncotherapists to initiate a correct form of treatment and improve the survival rate in breast carcinoma patients.

Authors declare that there are no conflict of interest regarding publication of this paper.

References

[1]. Perou CM, Sorlie T, Eilien MB, et aL Molecular portraits of huma breast tumours. *Nature* 2000;406(6797):747-752.

[2]. Sorlie T, Peron CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 2001;98:10869-10874

[3]. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, **14**: 1368–1376.

[4]. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

[5]. Prat A, Parker JS, Karginova 0, et aL Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* 2010;12:R68.
[6]. Lehmann BD, Bauer JA, Chen X, et aL Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies.] *Clin Invest* 2011;121:2750-2767
[7]. Rosen's Breast Pathology 4th edition chapter 45